Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1. The company continues with human trials and is getting funding that will enable the approval process to continue. BBLG also filed for a patent that stands to strengthen the company's intellectual portfolio.
